August 27th 2025
FDA approves updated COVID-19 vaccines for 2025-2026 but limits pediatric access, restricting use to older and high-risk groups.
Paxlovid EUA revised, emergency use still authorized in pediatric patients
January 29th 2024Though revisions have been made to the emergency use authorization (EUA), the FDA stated in a press release that the EUA will continue to authorize emergency use in children aged 12 years and older who are at high risk of severe COVID-19.
BNT162b2 COVID vaccine effective in children amid Delta, Omicron periods
January 17th 2024Investigators of a study published in Annals of Internal Medicine concluded that the BNT162b2 COVID-19 vaccine demonstrated efficacy against the Delta and Omicron variants of COVID-19 in children and adolescents, offering new, extended follow-up period data.